Quoin Pharmaceuticals Ltd
QNRXBuild a strategy around QNRX
Quoin Pharmaceuticals Ltd AI Insights
Informational only. Not investment advice.Snapshot
- Zero revenue with -14.2M operating loss TTM; 7.8M R&D spend (55% of opex) indicates pre-commercial biotech burning cash on development.[Operating Income TTM]
- Negative equity of -1.2M with liabilities (7.6M) exceeding assets (6.4M) - technically insolvent balance sheet.[Common Stockholders Equity]
- Cash of 1.8M vs -10.7M annual cash burn TTM = ~2 months runway without financing. Dilution or failure imminent.[Cash and Equivalents]
Watch Triggers
- Cash and Equivalents: Falls below 1M or financing announced — Sub-1M cash triggers going concern; financing terms reveal dilution severity
- Research and Development TTM: Significant reduction from 7.8M run rate — R&D cuts signal pipeline abandonment or pivot to wind-down
- Total Revenue TTM: Any revenue recognition — First revenue (licensing, milestone) would transform investment thesis
Bull Case
6.1M market cap on pre-revenue biotech with active R&D (7.8M TTM) - binary upside if pipeline advances to partnership or approval.
Enterprise value of 4.2M below cash-adjusted basis suggests market pricing in failure; any positive catalyst creates asymmetric return.
Bear Case
Negative equity (-1.2M) and 2-month cash runway make near-term dilution near-certain; current shareholders face massive value destruction.
EPS of -29.15 TTM with zero revenue path - no visibility to profitability; typical pre-revenue biotech failure profile.
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage QNRX's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Capital raise required within 3 months or operations cease; expect 50%+ dilution or reverse split.
- 1.8M cash vs 10.7M annual burn
- Negative equity precludes debt
- No revenue to fund operations
Valuation Context
Caveats
QNRX Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$314.26M | — | ||
$310.45M | — | ||
0.00 | — | ||
$0 | — | ||
$-518.00 | — | ||
0% | — | ||
0% | — | ||
$-13.54M | — | ||
-142% | -21.0% | — | |
Beta 5Y (Monthly) | unknown | — |
QNRX Dividend History
QNRX Stock Splits
QNRX SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
03/26/26 | 12/31/25 | 10-K | |
11/06/25 | 09/30/25 | 10-Q | |
08/07/25 | 06/30/25 | 10-Q | |
05/13/25 | 03/31/25 | 10-Q | |
03/13/25 | 12/31/24 | 10-K | |
11/08/24 | 09/30/24 | 10-Q | |
08/08/24 | 06/30/24 | 10-Q | |
05/09/24 | 03/31/24 | 10-Q | |
03/14/24 | 12/31/23 | 10-K | |
11/09/23 | 09/30/23 | 10-Q | |
08/03/23 | 06/30/23 | 10-Q | |
05/09/23 | 03/31/23 | 10-Q | |
03/15/23 | 12/31/22 | 10-K | |
11/10/22 | 09/30/22 | 6-K | |
08/18/22 | 06/30/22 | 6-K | |
08/11/22 | 03/31/22 | 6-K | |
04/14/22 | 12/31/21 | 20-F | |
12/20/21 | 09/30/21 | 6-K | |
11/23/21 | 06/30/21 | 6-K | |
08/11/22 | 03/31/21 | 6-K | |
04/14/22 | 12/31/20 | 20-F | |
12/20/21 | 09/30/20 | 6-K | |
11/23/21 | 06/30/20 | 6-K |